Healthcare [ 11/13 ] | Biotechnology [ 98/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 27, 23 | -0.56 Increased by +30% | -0.78 Increased by +28.21% |
| Aug 11, 23 | -0.11 Increased by +88.42% | -0.8 Increased by +86.25% |
| Apr 28, 23 | -1.29 Decreased by -35.79% | -4.05 Increased by +68.15% |
| Mar 24, 23 | -1.04 Decreased by -30% | -0.89 Decreased by -16.85% |
| Oct 28, 22 | -0.8 Decreased by -33.33% | -0.95 Increased by +15.79% |
| Aug 12, 22 | -0.95 Decreased by -171.43% | -0.6 Decreased by -58.33% |
| Apr 27, 22 | -0.95 Decreased by -46.15% | -0.52 Decreased by -82.69% |
| Mar 25, 22 | -0.8 Decreased by -433.33% | -0.72 Decreased by -11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -9.71 M Increased by +11.17% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 12 M Increased by +N/A% | -1.89 M Increased by +85.37% | Decreased by -15.71% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -19.11 M Decreased by -48.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -14.48 M Decreased by -58.47% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -10.93 M Decreased by -27.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -12.89 M Decreased by -137.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -12.9 M Decreased by -125.63% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -9.14 M Decreased by -59.87% | Decreased by N/A% Decreased by N/A% |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.